

Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab

Angela Fico,¹ Edoardo Mortato,¹ Claudia Paganini,¹ Marina Talamonti,² Cosimo Di Raimondo,² Dionisio Silvaggio,² Luca Bianchi,^{1,2} Marco Galluzzo^{1,2}

¹Department of Systems Medicine, University of Rome “Tor Vergata”; ²Dermatology Unit, Fondazione Policlinico “Tor Vergata”, Rome, Italy

Abstract

Paradoxical psoriasis is a rare but increasingly recognized adverse effect of anti-tumor necrosis factor- α (TNF- α) therapy, characterized by the onset or exacerbation of psoriatic lesions in patients treated for other immune-mediated conditions. We report the case of a 47-year-old woman with chronic plaque psoriasis who developed severe generalized pustular psoriasis (GPP) after six months of treatment with an adalimumab biosimilar. Given the extent and severity of the eruption and following inadequate response to previous conventional therapies, the patient was treated with brodalumab, an interleukin-17 receptor A (IL-17RA) inhibitor. Rapid and complete remission of both pustular and plaque psoriasis was achieved and maintained for over 60 weeks. This case supports the efficacy of IL-17 pathway blockade in managing paradoxical GPP and highlights the importance of prompt recognition and appropriate therapeutic switching in severe biologic-induced psoriasis.

Key words: paradoxical psoriasis; generalized pustular psoriasis; adalimumab biosimilar; brodalumab.

Correspondence: Marco Galluzzo, MD, Department of Systems Medicine, University of Rome “Tor Vergata”, via Montpellier 1, 00133 Rome, Italy.
E-mail: marco.galluzzo@uniroma2.it

Introduction

Tumor necrosis factor (TNF) inhibitors are well-established therapeutic options for patients with psoriasis. It is documented that TNF inhibitors, such as adalimumab, can worsen pre-existing psoriasis lesions or trigger the onset of new lesions, including pustular eruptions.¹ This is caused by an imbalance in cytokines, leading to what is known as “paradoxical reactions”. In this article, we share our experience with a paradoxical generalized pustular psoriasis (GPP) induced by adalimumab and treated very satisfactorily with brodalumab.

Case Report

A 47-year-old woman with a history of chronic plaque psoriasis since 2014, previously treated at another institution with topical corticosteroids, azathioprine, and cyclosporine, presented with recurrent disease flares unresponsive to these conventional therapies. In June 2016, she was hospitalized for widespread erythema and pustular/vesicular eruptions. Histopathological analysis from a skin biopsy suggested eczematous dermatitis, and oral corticosteroids led to temporary resolution. A subsequent flare in February 2017 required rehospitalization for similar erythematous-papular-pustular lesions. A second biopsy yielded overlapping features of eczema and psoriasis, again responsive to corticosteroid therapy. Between 2017 and 2022, the patient experienced recurrent psoriatic

activity despite intermittent systemic therapy. In April 2022, during a worsening of the disease, she was referred to our center. A decision was made to initiate treatment with a biosimilar of adalimumab targeting persistent plaque psoriasis on the arms and trunk. Clinical improvement was noted for five months. However, by October 2022, the patient developed a sudden and extensive pustular eruption involving the majority of her body surface area (BSA), accompanied by diffuse erythema and pruritus. No fever or systemic symptoms were present. Laboratory investigations, including hematologic and biochemical panels, were unremarkable. In the suspicion of a paradoxical reaction to adalimumab, the drug was discontinued, and since the patient refused a repeat biopsy, she was evaluated using confocal laser microscopy. Imaging revealed intra-corneal pustules containing hyper-reflective neutrophils (Figure 1). Based on clinical presentation and confocal microscopy, a diagnosis of GPP was made. Disease severity assessments showed a Generalized Pustular Psoriasis Area and Severity Index score of 40, BSA involvement of 60%, and a Dermatology Life Quality Index of 15. The Columbia-Suicide Severity Rating Scale screening was negative for depressive symptoms. Therapy with brodalumab was initiated at a dosage of 210 mg subcutaneously at weeks 0, 1, and 2, followed by maintenance dosing every two weeks. Significant clinical improvement was observed after the first two weeks, and by week 12, the patient achieved complete resolution of pustular lesions. Additionally, the plaque psoriasis was effectively controlled. After 60 weeks of continuous treatment, the patient remains in complete remission, without recurrence of either pustular or plaque-type lesions (Figures 2 and 3).

Discussion

Paradoxical psoriasis is a well-documented adverse event associated with anti-TNF- α therapies, often characterized by clinical and histopathologic features indistinguishable from idiopathic psoriasis.^{2,3} Among its various clinical phenotypes, GPP is one of the most severe and challenging to manage, given its acute presentation, potential systemic involvement, and refractoriness to conventional therapies.⁴ The immunopathogenesis of paradoxical psoriasis remains incompletely understood, but dysregulated cytokine signaling following TNF- α blockade appears to be central. Two predominant hypotheses have emerged. The first posits that inhibition of TNF- α leads to enhanced activation of plasmacytoid dendritic cells, resulting in increased production of type I interferons (especially IFN- α) and subsequent T cell activation, thereby establishing a self-sustaining inflammatory loop. The second hypothesis involves an imbalance in T cell subsets: TNF- α blockade favors the expansion of T helper (Th)17 cells while suppressing regulatory T cells, culminating in elevated interleukin (IL)-17 production – a key driver of psoriatic inflammation.⁵ In the context of GPP, recent advances have delineated a distinct inflammatory pathway involving the IL-36 cytokine family.⁶ Mutations in *IL36RN*, encoding the IL-36 receptor antagonist, have been identified in a subset of GPP patients, resulting in unopposed IL-36 activity. This promotes exaggerated neutrophilic inflammation and keratinocyte activation. Importantly, IL-36 and IL-17 exhibit a synergistic interplay: IL-36 promotes Th17 polarization and IL-17 secretion,⁷ while IL-17 further upregulates IL-36 expression in keratinocytes.⁸ This positive feedback loop amplifies cutaneous inflammation and drives the hallmark features of GPP, including widespread sterile pustules and systemic symptoms. Given this pathogenic framework, targeting the IL-17 axis represents a rational therapeutic strategy.⁹ Among IL-17 inhibitors, brodalumab offers a unique mechanism of action by antagonizing the IL-17 receptor A (IL-17RA), thereby blocking signaling from multiple IL-17 family cytokines (including IL-17A, IL-17F, and others).¹⁰ This broader inhibition may be particularly effective in severe and refractory cases such as paradoxical GPP, where multiple IL-17 isoforms and

cytokine loops are implicated. Our clinical case underscores this therapeutic potential. The temporal association with adalimumab administration, clinical presentation, and rapid improvement after discontinuation strongly support a diagnosis of paradoxical GPP. The lack of systemic symptoms and the confocal microscopy findings further supported this conclusion in the absence of histopathological confirmation. The patient achieved complete and sustained remission with brodalumab, with both pustular and plaque components resolving rapidly. Notably, confocal microscopy played a valuable diagnostic role in our case, providing real-time, non-inva-




Figure 1. Section details under focal laser microscopy examination exhibit intracorneal pustules with hyperreflective neutrophils.



Figure 2. GPP eruption before (a) and after (b) treatment with brodalumab.




Figure 3. A particular of GPP eruption before (a-c) and after (b-d) treatment with brodalumab.

sive visualization of psoriasiform features and aiding in the differential diagnosis without the need for an invasive biopsy. This highlights its potential utility in complex or atypical dermatologic presentations. Management of paradoxical GPP typically necessitates discontinuation of the inciting anti-TNF agent.⁴ While some patients respond to topical therapies, systemic treatment is often required. Switching to another anti-TNF agent may carry a risk of recurrence, suggesting a class effect.¹¹ In contrast, switching to a different biologic class, particularly IL-17 inhibitors, has shown superior efficacy. Brodalumab has demonstrated robust and durable responses in both clinical trials and real-world reports of paradoxical psoriasis, including pustular variants.¹²⁻¹⁴

Conclusions

In conclusion, paradoxical GPP represents a distinct inflammatory reaction triggered by TNF- α inhibition, driven by complex cytokine dysregulation involving the IL-17/IL-36 axis. IL-17 inhibitors, and especially brodalumab, due to their receptor-blocking mechanism, provide a targeted and effective treatment option. Our case illustrates not only the therapeutic success of brodalumab in this context but also the emerging role of confocal microscopy as a diagnostic adjunct in dermatology.

References

1. Zheng J, Gao Y, Ding Y. Successful management of infliximab-induced generalized pustular psoriasis without therapy discontinuation in a patient with psoriatic arthritis. *Dermatol Ther* 2019;32:e13132.
2. Bucalo A, Rega F, Zangrilli A, et al. Paradoxical Psoriasis Induced by Anti-TNF α Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers. *Int J Mol Sci* 2020;21:7873.
3. Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. *Aliment Pharmacol Ther* 2011;34:1318-27.
4. Brown G, Wang E, Leon A, et al. Tumor necrosis factor- α inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience. *J Am Acad Dermatol* 2017;76:334-41.
5. Ma HL, Napierata L, Stedman N, et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. *Arthritis Rheum* 2010;62:430-40.
6. Gössinger E, Dodiuk-Gad R, Mühleisen B, et al. Generalized Pustular Psoriasis, Acute Generalized Exanthematous Pustulosis, and Other Pustular Reactions: A Clinical Review. *Dermatol Clin* 2024;42:317-28.
7. Uppala R, Tsoi LC, Harms PW, et al. "Autoinflammatory Psoriasis" - Genetics and Biology of Pustular Psoriasis. *Cell Mol Immunol* 2021;18:307-17.
8. Krueger J, Puig L, Thaçi D. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. *Am J Clin Dermatol* 2022;23:51-64.
9. Rosi E, Fastame MT, Di Cesare A, et al. Targeting IL-17A for the treatment of pustular psoriasis: a comprehensive review. *Expert Opin Biol Ther* 2022;22:1475-87.
10. Gisondi P, Girolomoni G. Brodalumab in the treatment of chronic plaque psoriasis. *Expert Opin Biol Ther* 2020;20:1175-86.
11. Almutairi D, Sheasgreen C, Weizman A, Alavi A. Generalized Pustular Psoriasis Induced by Infliximab in a Patient With Inflammatory Bowel Disease. *J Cutan Med Surg* 2018;22:507-10.
12. Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. *Br J Dermatol* 2017;176:741-51.
13. Avallone G, Maronese CA, Murgia G, et al. Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study. *J Clin Med* 2023;12:1662.
14. Cortonesi G, Trovato E, Orsini C, et al. Paradoxical psoriasis induced by anti-TNF-alpha successfully treated with brodalumab. *Dermatol Ther* 2021;34:e15084.

Received: 23 April 2025; Accepted: 20 May 2025.

Conflict of interest: MG and MT declare to have acted as speakers and/or consultants for AbbVie, Almirall, Eli-Lilly, Johnson & Johnson, LeoPharma, Novartis, and Sanofi outside the submitted work; LB declares to have acted as a speaker and/or consultant for AbbVie, Almirall, Eli-Lilly, Johnson & Johnson, LeoPharma, Novartis, Pfizer, Sanofi, and UCB outside the submitted work. The other authors declare no conflict of interest.

Ethics approval and consent to participate: no ethical committee approval was required for this case report by the Department because this article does not contain any studies with human participants or animals. Informed consent was obtained from the patient included in this study.

Consent for publication: the patient gave her written consent to use her personal data for the publication of this case report and any accompanying images.

Availability of data and materials: data supporting the findings of this study are available upon reasonable request from the corresponding author.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).